Key Words: Innate Pharma S.A. (NASDAQ: IPHA) shares gained 40.9% to close at $8.10 as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021. SVB Leerink maintained Innate Pharma with an Outperform and raised the price target from $7 to $9. Innate Pharma...
AS yall can see volume died down on this one but we will look to catch it if volume does decide to pick up this set up is worth watch
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma,...
-the news published may help to break the down trend, and the oblic resistance caping the price since years ! weekly resistance at 3.42 - tonight, closure at 3.22, Target is to reach at least 3.9 so another 20% same as today,intraday or in swing for a few days; - what's your view guys ? beware, below 4.45, the mid long term trend is down.
MACD is curling and the price closed above the 23.6% Fib level after testing resistance at 4.8o I would like to see it retest and hold 4.65 before going long for a swing trade. First target 5.53